TIAA CREF INVESTMENT MANAGEMENT LLC - THERAVANCE BIOPHARMA INC ownership

THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 99 filers reported holding THERAVANCE BIOPHARMA INC in Q4 2016. The put-call ratio across all filers is 0.66 and the average weighting 0.4%.

Quarter-by-quarter ownership
TIAA CREF INVESTMENT MANAGEMENT LLC ownership history of THERAVANCE BIOPHARMA INC
ValueSharesWeighting
Q1 2019$3,852,000
-10.1%
169,910
+1.5%
0.00%0.0%
Q4 2018$4,283,000
-58.8%
167,371
-47.4%
0.00%0.0%
Q3 2018$10,386,000
+267.9%
317,932
+155.4%
0.00%
+50.0%
Q2 2018$2,823,000
-6.7%
124,471
-0.3%
0.00%0.0%
Q1 2018$3,027,000
-13.8%
124,812
-0.8%
0.00%0.0%
Q4 2017$3,510,000
-23.1%
125,849
-5.6%
0.00%
-33.3%
Q3 2017$4,563,000
-25.7%
133,266
-13.6%
0.00%
-25.0%
Q2 2017$6,142,000
+31.7%
154,158
+21.7%
0.00%
+33.3%
Q1 2017$4,665,000
+8.0%
126,686
-6.5%
0.00%0.0%
Q4 2016$4,320,000
-2.6%
135,501
+10.7%
0.00%0.0%
Q3 2016$4,436,000
+56.5%
122,401
-2.0%
0.00%
+50.0%
Q2 2016$2,834,000
+73.8%
124,919
+44.0%
0.00%
+100.0%
Q1 2016$1,631,000
+22.3%
86,779
+6.6%
0.00%0.0%
Q4 2015$1,334,000
+43.1%
81,404
-4.0%
0.00%0.0%
Q3 2015$932,000
-14.2%
84,816
+1.6%
0.00%0.0%
Q2 2015$1,086,000
-25.4%
83,447
-0.6%
0.00%0.0%
Q1 2015$1,456,000
+16.3%
83,9310.0%0.00%0.0%
Q4 2014$1,252,000
-49.6%
83,931
-22.1%
0.00%
-50.0%
Q3 2014$2,483,000
-34.8%
107,743
-9.7%
0.00%
-33.3%
Q2 2014$3,806,000119,3780.00%
Other shareholders
THERAVANCE BIOPHARMA INC shareholders Q4 2016
NameSharesValueWeighting ↓
Woodford Investment Management Ltd 11,213,879$254,331,00030.84%
Cormorant Asset Management, LP 1,300,000$29,484,0002.18%
Baupost Group 9,309,168$211,132,0001.85%
SENZAR ASSET MANAGEMENT, LLC 27,397$621,0001.79%
ARMISTICE CAPITAL, LLC 1,180,000$26,762,0001.75%
Old West Investment Management, LLC 111,101$2,519,0001.27%
Chescapmanager LLC 403,321$9,147,0001.06%
Virtus ETF Advisers LLC 30,055$682,0000.60%
Rock Springs Capital Management LP 652,600$14,801,0000.57%
Foundation Asset Management, LP 27,154$616,0000.53%
View complete list of THERAVANCE BIOPHARMA INC shareholders